Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 2Prostatic Neoplasms, Castration-Resistant 1Neoplasm Metastasis 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1

Interventions

enzalutamide 14Docetaxel 7radium Ra 223 dichloride 6Abiraterone Acetate 6Prednisone 5darolutamide 4abiraterone 3olaparib 2niraparib 2atezolizumab 2apalutamide 2zimberelimab 1xentuzumab 1tasquinimod 1sacituzumab govitecan 1sabizabulin 1quemliclustat 1ipatasertib 1ibrutinib 1gedatolisib 1gallium 68 PSMA-11 1fludrocortisone acetate 1cabazitaxel 1Rosuvastatin Calcium 1Radium-223 1Pluvicto 1Pioglitazone 1Nivolumab 1JNJ-64619178 1JNJ-64264681 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Prostatic Neoplasms, Castration-Resistant × Radium-223 × Clear all
NCT03563014 2020-05-20

BELFIGO

Bayer

Completed
164 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡